Sectors
PPCB
Propanc Biopharma, Inc.
1.44
1 x 1.36
16 x 1.49
bid
ask
+
0.06
4.35%
undefined @ 04:00 PM
1.41 -0.03 (2.08%)
| Ytd | -89.27% | |
| 1y | -98.71% |
1.36
day range
1.47
1.30
52 week range
270.25
| Open | 1.41 | Prev Close | 1.38 | Low | 1.36 | High | 1.47 | Mkt Cap | 1.24M |
| Vol | 102.71K | Avg Vol | 3.96M | EPS | -8.04 | P/E | -0.18 | Forward P/E | N/A |
| Beta | 3.49 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.73 | 200-d Avg | 11.24 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 6.40M | ||
| Research and Development Expense | 169.66K | ||
| Selling, General and Administrative Expense | 6.23M | ||
| Operating Income | -6.40M | ||
| Interest Expense | 38.27K | ||
| Net Income | -6.36M | ||
| Net Income Common Stock | -6.36M | ||
| Net Income Common Stock (USD) | -6.36M | ||
| Consolidated Income | -6.36M | ||
| Earnings per Basic Share | -7.00 | ||
| Earnings per Basic Share (USD) | -7.00 | ||
| Earnings per Diluted Share | -7.00 | ||
| Earning Before Interest & Taxes (EBIT) | -6.32M | ||
| Earning Before Interest & Taxes (USD) | -6.32M | ||
| Weighted Average Shares | 897.10K | ||
| Weighted Average Shares Diluted | 897.10K | ||
| Balance Sheet | |||
| Cash and Equivalents | 443.70K | ||
| Cash and Equivalents (USD) | 443.70K | ||
| Current Assets | 8.22M | ||
| Property, Plant & Equipment Net | 50.81K | ||
| Total Assets | 14.33M | ||
| Debt Current | 543.61K | ||
| Total Debt | 573.87K | ||
| Current Liabilities | 3.48M | ||
| Debt Non-Current | 30.27K | ||
| Total Liabilities | 3.51M | ||
| Accumulated Retained Earnings (Deficit) | -140.84M | ||
| Accumulated Other Comprehensive Income | 1.23M | ||
| Shareholders Equity | 9.83M | ||
| Shareholders Equity (USD) | 9.83M | ||
| Assets Non-Current | 6.11M | ||
| Total Debt (USD) | 573.87K | ||
| Liabilities Non-Current | 30.27K | ||
| Trade and Non-Trade Payables | 973.69K | ||
| Tax Assets | 11.06K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 6.59K | ||
| Net Cash Flow from Financing | 981.61K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -117.53K | ||
| Capital Expenditure | -154.00 | ||
| Issuance (Repayment) of Debt Securities | -18.39K | ||
| Net Cash Flow from Investing | -154.00 | ||
| Net Cash Flow from Operations | -1.14M | ||
| Effect of Exchange Rate Changes on Cash | 43.45K | ||
| Share Based Compensation | 1.78M | ||